Suzanne Elvidge
ARTICLES BY SUZANNE ELVIDGE
-
![Sangamo-TxCell_headshots_450x300]( "The Sangamo And TxCell Story: How Two Companies Built A Deal")
The Sangamo And TxCell Story: How Two Companies Built A Deal3/1/2019What makes a successful merger? Here we look at the 2018 merger between genome-therapy-focused company Sangamo Therapeutics and TxCell, which focuses on regulatory T-cell (Treg) development for immunological diseases.
-
![IO Trends - Asthika Goonewardene]( "IO Building A New Future For Cancer Treatment")
IO Building A New Future For Cancer Treatment3/1/2019A primer on immuno-oncology and what’s next for this promising field of cancer treatments.
-
![CellandGene_Cuende]( "Combatting Unproven Cell And Gene Therapies Through Regulation And Education")
Combatting Unproven Cell And Gene Therapies Through Regulation And Education2/1/2019According to the inaugural annual report from the International Society for Cell and Gene Therapy (ISCT), the number of CGTs with marketing authorization increased by 45 percent between 2015 and September 2018.
-
![Germany Bioincubators_450x300]( "Germany’s Plan To Foster And Grow Biopharma Innovation")
Germany’s Plan To Foster And Grow Biopharma Innovation1/2/2019In Germany, bioclusters and technology parks have been created to encourage and support pharmaceutical innovation in the region.
-
![Brett Davis_450X300]( "Biopharma Bringing RWE Into The Real World")
Biopharma Bringing RWE Into The Real World11/7/2018Real-world evidence is playing an increasingly important role throughout the drug development lifecycle—as outlined in Deloitte's latest survey on the life sciences industry's RWE capabilities— and companies are really beginning to take notice.
-
![david smaldone_450x300]( "EU Drug Safety Through FMD Serialization Readiness")
EU Drug Safety Through FMD Serialization Readiness11/7/2018Falsified medicines are a critical challenge to the safety of patients and to the reputation of the pharmaceutical industry. Serialization is a major step toward drug safety across the EU but has brought with it a set of challenges that national authorities and companies are tackling.
-
![M. Pintore_Alsace Bio Valley_450x300]( "French Bioclusters Refocus Collaboration Efforts")
French Bioclusters Refocus Collaboration Efforts8/2/2018In 2018, seven French bioclusters announced they were planning to work more closely together to, among other things, improve the attractiveness of France for medical and pharma science and re-industrialize the country.
-
![Sara]( "Mapping The Swedish Precision Medicine Industry Landscape")
Mapping The Swedish Precision Medicine Industry Landscape6/1/2018Sweden's approach to maintaining innovation and effectiveness in drug development relies on precision medicine, as outlined in the new SwedenBIO report "Precision Medicine – The Swedish Industry Guide 2018."
-
![UK Flag]( "State Of A Nation: The UK Is Facing Up To Global Drug Discovery Challenges")
State Of A Nation: The UK Is Facing Up To Global Drug Discovery Challenges5/2/2018The "State of the Discovery Nation 2018" report is based on surveys and more than 100 in-depth interviews with senior executives at U.K. drug-discovery companies. The report looks at the current status of U.K. drug discovery and its challenges and opportunities.
-
![Oxford Bio 450x300]( "Deal Building From Testing The Water To Hitting The Market")
Deal Building From Testing The Water To Hitting The Market2/7/2018The story of how Oxford BioMedica won a key contract from Novartis to provide the commercial and clinical supply of lentiviral vectors used to produce the Big Pharma's CAR-T cell therapy Kymriah.
